Literature DB >> 7987642

p53 and human cancers.

D P Lane1.   

Abstract

Mutations in the p53 gene are one of the commonest specific genetic changes found in human cancer. The p53 gene is not required for normal development but lack of p53 function confers an enormously elevated risk of developing cancer, thus it seems truly to act as a tumour suppressor gene. The p53 protein is normally present in minute amounts in cells but when cells are exposed to genotoxic stimuli p53 levels rise rapidly and initiate a programme of cell death, probably by means of transcriptional regulation. This response is lost in many tumour cells as they have either inactivated their p53 genes by mutation or blocked the activity of p53 through the production of proteins that bind to it and neutralise it. Mutant p53 proteins accumulate to high levels in many cancer cells and the p53 protein and the p53 response to DNA damage represent key points for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987642     DOI: 10.1093/oxfordjournals.bmb.a072911

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  33 in total

Review 1.  DNA mismatch repair genes and colorectal cancer.

Authors:  J M Wheeler; W F Bodmer; N J Mortensen
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

Review 2.  Thioredoxin reductase.

Authors:  D Mustacich; G Powis
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

3.  Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter.

Authors:  J Bian; Y Sun
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 4.  Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis.

Authors:  Javier S Burgos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

5.  The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis.

Authors:  D R Brown; C A Thomas; S P Deb
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

6.  Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: molecular dynamic and immunologic analyses.

Authors:  P W Brandt-Rauf; J M Chen; M J Marion; S J Smith; J C Luo; W Carney; M R Pincus
Journal:  J Protein Chem       Date:  1996-05

7.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

Review 8.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

9.  The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.

Authors:  Eva Roubalová; Veronika Kvardová; Roman Hrstka; Sárka Borilová; Eva Michalová; Lenka Dubská; Petr Müller; Petr Sova; Borivoj Vojtesek
Journal:  Invest New Drugs       Date:  2009-06-05       Impact factor: 3.850

10.  Silibinin ameliorates oxidative stress induced aberrant crypt foci and lipid peroxidation in 1, 2 dimethylhydrazine induced rat colon cancer.

Authors:  Nagarajan Sangeetha; Selvaraj Aranganathan; Namasivayam Nalini
Journal:  Invest New Drugs       Date:  2009-03-10       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.